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Abstract: The chemokine receptor CCR5 regulates trafficking of immune cells of the 
lymphoid and the myeloid lineage (such as monocytes, macrophages and immature 
dendritic cells) and microglia. Because of this, there is an increasing recognition of the 
important role of CCR5 in the pathology of (neuro-) inflammatory diseases such as 
atherosclerosis and multiple sclerosis. Expression of CCR5 is under the control of a 
complexly organized promoter region upstream of the gene. The transcription factor 
cAMP-responsive element binding protein 1 (CREB-1) transactivates the CCR5 P1 
promoter. The cell-specific expression of CCR5 however is realized by using various 
epigenetic marks providing a multivalent chromatin state particularly in monocytes. Here 
we discuss the transcriptional regulation of CCR5 with a focus on the epigenetic 
peculiarities of CCR5 transcription. 
Keywords: transcription regulation; CCR5; epigenetics; DNA methylation; multivalent 
chromatin 
 
1. Introductions 
CC chemokine receptor 5 (CCR5), a receptor for the CC chemokines macrophage inflammatory 
protein-?? (MIP-1?), macrophage inflammatory protein-?? (MIP-1?), and regulated and normal T cell 
expressed and secreted (RANTES), regulates trafficking of lymphoid cells such as memory/effector 
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Th1 lymphocytes, or cells of the myeloid lineage (e.g., monocytes, macrophages, immature dendritic 
cells) and microglia [1?3]. As such, CCR5 is implicated in the pathogenesis of various inflammatory 
diseases such as atherosclerosis and multiple sclerosis [4?7]. This is illustrated in atherosclerotic 
mouse models, in which Ccr5 knock-out mice show less neointima formation and an increase in 
production of the anti-inflammatory IL-10 molecule by vascular smooth muscle cells (vSMCs) [8,9]. 
One of the ligands for the CCR5 receptor, CCL5 or RANTES, has also been shown to be involved in 
unstable angina pectoris, which usually results from atherosclerosis [10]. Furthermore, CCR5 also 
functions as a co-receptor for HIV-1 [11?13]. Importantly, individuals with a mutated CCR5 receptor 
appear to be near-completely protected for HIV-1 infection [10,13]. Notably, CCR5 expression is 
markedly upregulated upon T cell activation, which allows the activated T cells to migrate towards 
site(s) of inflammation [14?18]. 
Upon encountering a pathogen, antigen-presenting cells will present the antigenic peptide to resting 
naive T cells, which results in the generation and activation of antigen-specific T cells [19,20]. After 
activation, the T cells migrate to the site of inflammation, guided by chemokine receptors [21]. 
Similarly, circulating monocytes are also attracted to inflammatory sites by chemokine receptors, 
where they then can differentiate into e.g., macrophages or microglia [22?24]. Atherosclerosis and 
multiple sclerosis are greatly characterized by inflammatory lesions, consisting of T cells and 
macrophages or microglia, respectively [25?27]. The chemokine receptor CCR5 is implicated in the 
pathogenesis of both of these diseases [8,9,28,29]. 
With CCR5 being implicated in various (inflammatory) diseases and as co-receptor for HIV-1 
infection, much work has been put into the transcriptional regulation of CCR5. CCR5 transcription is 
controlled by a complex promoter structure. Although a number of transcription factors, including 
CREB-1, have been shown to play a role in CCR5 transcriptional regulation, its cell type specific 
expression is also controlled by epigenetic mechanisms. In some cell types the chromatin status of 
CCR5 is rather peculiar in that it is hallmarked by various multivalent states. In this review we will 
discuss the regulation of CCR5 expression, with the focus on epigenetic regulation and the possible 
pharmacological intervention in these epigenetic regulatory processes. 
2. Genomic Organization 
Mummidi et al. previously elucidated the organization and promoter usage of the CCR5 gene 
(Figure 1) [16,30]. Two distinct functional promoter regions for the CCR5 gene were identified using 
luciferase-reporter constructs containing CCR5 regulatory regions: a downstream promoter region, 
nowadays designated as P1, and an upstream promoter region, designated P2. The P2 promoter in front 
of exon 1 was identified as a weaker promoter than the P1 promoter, which is located near exon 2b 
(Figure 1) [16]. Using 5' RACE and RT-PCR the authors found four exons and two introns in the 
genomic organization of CCR5. The authors suggested that two full-length transcripts arose from 
promoter P1 and numerous truncated transcripts (i.e., missing exon 1) arose from promoter P2. 
Between exon 2a and exon 2b there is no intron. Both the truncated and the full-length transcripts give 
rise to the full length CCR5 protein. The two different full-length transcripts designated CCR5A and 
CCR5B differ by 235 nucleotides, corresponding to a lack of exon 2 in the CCR5B transcript. 
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Both P1 and P2 lack the canonical TATA and CCAAT motifs, although in P1 a non-classical 
TATA-box can be found. Unlike other TATA-less promoters, the CCR5 promoters have a relatively 
low CpG content. 
Figure 1. Promoter organization of the CCR5 gene. CCR5 transcription is initiated from 
two distinct promoters. Full-length transcripts arise from promoter P1 and truncated 
transcripts from promoter P2. The black arrow indicates the most responsive CREB-1 site. 
Other transcription factors attributed to CCR5 transcription regulation are depicted with 
gray arrows. Grey circles indicate CpG residues. The region investigated for epigenetic 
regulation ??? ?????????? ??????? ?????????????? ??? ?????????? ??? ?????? ????????? Adapted  
from [31]. 
 
3. CCR5 Regulation by Transcription Factors 
In their initial characterization of the CCR5 promoter, Liu and coworkers suggested that CCR5 
transcription could be up-regulated by NF-?? [32]. Indeed, others and we found several potential 
binding sites for NF-??????????CCR5 P1-promoter [33]. However, the results of the study by Kuipers  
et al. indicate that CCR5 expression is neither induced nor modulated by NF-?? [33]. In addition, 
these authors also found binding sites for interferon regulatory factors (IRFs) and CREB-1 in the 
CCR5 P1- and P2-promoters. Like for NF-?B and in contrast to CREB-1, Kuipers et al. could not 
establish a role for the IFN-?? ???????? ??????????? ???????? ???CCR5 transcription. By using various 
reporter assays, as well as by competition for CREB-1 binding-sites by inducible cAMP early 
repressor (ICER), which is induced by forskolin treatment, the authors concluded that CCR5 
transcription is regulated by CREB-1 [33]. More recently, Banerjee et al. also showed that in the TF-1 
human bone marrow progenitor cell line, CCR5 is regulated at the transcriptional level by the 
cAMP/PKA/CREB pathway [34]. 
In line with an important role for CREB-1 in CCR5 expression are the transcription levels of 
CREB-1 isoforms and ICER in activated versus naïve CD4+ T cells. Upon activation of CD4+ T cells, 
the relative transcription levels of CREB-1 isoforms increase whereas transcription levels of ICER 
decrease [31]. 
The site most responsive to the CREB-1-mediated transactivation is located in the downstream  
P1-promoter (Figure 1). Promoter constructs using the upstream promoter however were unresponsive to 
CREB-1. This suggests a repressive function of the upstream promoter region. This hypothesis is 
underscored by the fact that the longest downstream promoter construct, including part of the upstream 
region, is less responsive to CREB-1 than truncated downstream promoter constructs. These findings 
corroborate those of others that mapped a repressive element, corresponding to a region upstream, 
affecting the CCR5 promoter [32,35,36]. Besides an important role for CREB-1 in the transcriptional 
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regulation of CCR5, several other studies have revealed also a contribution for Oct1 and Oct2 [15,37], 
NF-AT [32], YY1 [38], GATA-1 [39], and KLF2 [40] in the modulation of CCR5 transcription. 
4. Epigenetic Regulation 
In addition to the transcription factors discussed above, most if not all genes are also regulated at 
the transcriptional level by epigenetic processes. Since CCR5 is only expressed in a subset of T 
lymphocytes, monocytes, macrophages, or dendritic cells the contribution of epigenetic mechanisms in 
the cell-type specific transcriptional regulation of CCR5 was proposed and investigated [31,33]. 
In the cell nucleus, DNA is present as a protein-DNA complex called chromatin. The basic repeating 
unit of chromatin is the nucleosome, which consists of 146bp of DNA wrapped around an octamer of 
histones, comprising pairs of the core-histones H2A, H2B, H3 and H4. The structure of the chromatin 
can be altered by epigenetic regulation through modification of DNA and of histones. In this way, 
epigenetic regulation controls gene transcription by modifying the chromatin architecture in such a 
way that it influences the accessibility of DNA for transcription factors. Note, these epigenetic 
modifications are reversible allowing the chromatin structure to switch between open and closed states. 
This form of transcriptional control is thought to form also the basis for cell-to-cell inheritance of gene 
expression profiles [41]. Epigenetic modifications include methylation of DNA at CpG residues in gene 
promoters and post-translational modifications of histone tails such as acetylation and methylation [42]. 
DNA methylation is perhaps one of the best-studied epigenetic modifications. CpG residues are 
underrepresented in the human genome but are highly enriched in so-called CpG islands in most gene 
promoters [43,44]. As a general rule of thumb, gene expression is associated with unmethylated CpGs 
in gene promoters, while CpG methylation in gene promoters is associated with transcriptional 
repression [45]. More recently, the involvement of additional CpG containing regions, the so-called 
CpG island shores, at more distal locations from gene promoters in gene transcription has become 
apparent [46]. Mechanisms that underlie gene repression by histone methylation involve, amongst 
others, tri-methylation of histone H3 at lysine 9 (3MeK9H3) and at lysine 27 (3MeK27H3), and of 
histone H4 at lysine 20 (3MeK20H4) in proximal promoter chromatin [47?50]. Counteracting these 
repressive modifications are the transcriptionally permissive modifications tri-methylation of histone 
H3 at lysine 4 (3MeK4H3) and histone acetylation [50?52]. 
Together these modificatio???????????histone code?? like the genetic code, that controls transcription 
levels of genes [53]. As mentioned above, one important trait of epigenetic regulation is that 
modifications to DNA and to histone tails are reversible. Furthermore, these activities are functionally 
linked [54]. 
4.1????????????? Epigenetic Regulation 
In the case of the CCR5 locus, non-expressing cells such as Jurkat (a T leukemia cell line) cells 
have a densely methylated promoter. Conversely, cells on which CCR5 is highly expressed display a 
virtually unmethylated CCR5 promoter region [31]. 
In a traditional view of epigenetic regulation, chromatin could either be in open (euchromatin) or 
closed (heterochromatin) conformation (Figure 2) [55,56]. Intermediate chromatin states were thought 
to be a transition between either hetero- or euchromatin and were thought to be only short lived [57]. 
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When transcription was occurring, a gene promoter was enriched in acetylated lysine 9 in histone H3 
(AcK9H3) and 3MeK4H3, whereas transcriptionally silenced genes where enriched in 3MeH3K27 and 
3MeH3K9 [52,58]. 
Figure 2. Schematic representation of chromatin states encountered in the CCR5 locus. 
Chromatin can be marked by mainly repressive or mainly permissive marks, regarded as 
the classical euchromatin (green) and ????????????????????????????????????????? regulation). 
Nowadays it is widely appreciated that more complex forms of chromatin exist, hallmarked 
by both repressive and permi?????? ?????? ??? ???? ????? ?????? ?????? ?????????? regulation). 
Note: For clarity DNA-methylation is drawn on the internucleosomal-DNA, whereas it has 
been shown that methylated DNA co-localizes also with nucleosomes [59]. 
 
When comparing activated and naïve CD4+ T cells, the CCR5 locus displays such a classical  
pattern [31,33]. Naïve CD4+ T cells are characterized be relatively low levels of AcH3 and relatively 
high levels of the repressive mark 3MeK20H4. When compared to activated T cells, naïve T cells also 
contain high levels of 3MeK27H3. Upon activation the repressive marks in the chromatin of the CCR5 
promoter are replaced by activating marks. Chromatin of the CCR5 promoter in activated CD4+ T cells 
is almost exclusively covered with the activating marks AcH3 and 3MeK4H3. In other cell types 
however, the chromatin makeup of the CCR5 locus is more complex. 
4.2. ????-?????????? Epigenetic Regulation 
Bivalent chromatin structures, composed of both 3MeK4H3 and 3MeK27H3, were first found in 
embryonic stem cells. In these cells, bivalent states marked genes encoding transcription factors that 
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play an essential role in development. It was proposed that these bivalent states would silence 
developmental genes while keeping them poised for activation. Upon differentiation, this bivalent state 
would be lost [60]. Later work not only identified bivalent, but also tri- and tetravalent chromatin 
states [61]. Furthermore, multivalent chromatin states where found to also occur in differentiated  
cells [31,61]. Lastl?? ??? ??????? ???? ????? ?????????? ???????? chromatin, is not completely silenced as 
proposed initially. Some transcripts arise from multivalent chromatin, thus multivalent chromatin 
might be a mechanism for transcriptional fine-tuning [62]. It is thought therefore that these multivalent 
states may be of importance for the control of gene expression in the activation of T cells and the 
differentiation of monocytes [62]. Chromatin Immunoprecipitation (ChIP) experiments performed on 
the CCR5 promoter region revealed that this promoter is extensively covered by multivalent marks [31]. 
In CCR5-expressing monocytes, the CCR5 promoter is covered with high levels of AcH3, but also 
with relative high levels of 3MeK9H3 and 3MeK27H3 and an intermediate level of 3MeK20H4. The 
histone modifications in monocytes are accompanied with relatively high levels of DNA methylation 
(Figure 2). Yet despite all these repressive modifications monocytes show CCR5 transcription levels that 
are markedly higher then naïve CD4+ T cells, albeit at a lower level than in activated CD4+ T cells [31]. 
Monocytes have the ability to differentiate into macrophages and dendritic cells. Upon differentiation 
CCR5 expression is lost. The fact that monocytes display high amounts of repressive marks in 
conjunction with histone acetylation may reflect the potential to rapidly shut down CCR5 transcription 
upon differentiation. The observed multivalent chromatin state of CCR5 as such might reflect the 
central role of CCR5 in the regulation of lymphoid cell trafficking. 
4.3. Epigenetic Intervention 
Epigenetic modifications are reversible and can be modulated by small molecule inhibitors. With 
CCR5 cell-type specific transcription being achieved by epigenetic regulation, small molecule 
inhibitors could modulate CCR5 transcription. Jurkat cells do not express CCR5, however it was 
demonstrated by using promoter constructs that Jurkat cells contain all the necessary transcription 
factors to achieve CCR5 transcription [32]. 
In Jurkat cells, DNA of the CCR5 promoter is densely methylated. Furthermore, chromatin 
encompassing the promoter region hardly contains AcH3 and is devoid of 3MeK4H3. Finally, the 
CCR5 promoter is enriched for the repressive chromatin marks 3MeK9H3, 3MeK27H3 and 
3MeK20H4. Using a combination of a DNMT inhibitor (Zebularine), a lysine methyltransferase 
inhibitor (DZNep) and a histone deacetylase (HDAC) inhibitor (MS-275; specific for the class 1 
HDACs 1 and 3 [63?65]) the expression of the CCR5 gene could be activated in Jurkat cells but also in 
other CCR5-deficient leukemic T cell-lines (Figure 3). Interestingly mono-treatment with these inhibitors 
showed only a very small effect [31]. Matalon et al. also have shown that treatment of CD4+ T cells 
and monocytes with HDAC inhibitors modulates the expression of CCR5 in these cell types [66]. 
Together, these observations underscore that CCR5 transcription is actively controlled by epigenetic 
mechanisms. It should be noted however, that these inhibitors act genome-wide and as such targeting 
these inhibitors to specific genes may prove to be challenging. Meanwile, some of these epigenetic 
inhibitors have been in clinical use already for decades (e.g., for the management of epilepsy with 
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Depakene, or valproic acid), despite the fact that they act genome-wide and they seem to be well 
tolerated [67,68]. 
Figure 3. Schematic representation of the working mechanism for the pharmacological 
intervention in CCR5 transcription. Re-expression was achieved by combinatorial treatment 
with a DNMT inhibitor (DNMTi, Zebularine), a lysine methyltransferase inhibitor (KMTi, 
DZNep) and a HDAC inhibitor (HDACi, MS-275). Adapted from [31]. 
 
5. Conclusions 
Transcription of CCR5 is achieved by a complex interplay of transcription factors and various forms 
of epigenetic regulation. Cell type-specific transcription of CCR5 is achieved by epigenetic regulation. 
Epigenetic regulation also allows for rapid transcriptional shutdown or initiation of the CCR5 locus 
upon differentiation of various cell types. This epigenetic regulation is a perfect entry point for 
pharmaceutical intervention. Given the importance of CCR5 in numerous inflammatory diseases and 
as co-receptor for HIV-1 gaining entrance into cells, pharmaceutical intervention in the epigenetic 
regulation of CCR5 transcription may prove to be valuable in future disease management. 
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